Jyong Biotech (MENS) Other Non-Current Assets (2024 - 2025)
Jyong Biotech's (MENS) quarterly Other Non-Current Assets came in at $6000.0 in Q4 2025, little changed year-on-year from $6000.0 in Q4 2024, and down 14.29% quarter-over-quarter from $7000.0 in Q2 2025.
Jyong Biotech (MENS) Other Non-Current Assets (2024 - 2025) Analysis & Trends
Jyong Biotech's Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $6000.0 for Q4 2025.
- On a quarterly basis, Other Non-Current Assets changed 0.0% year-over-year to $6000.0 in Q4 2025; TTM through Dec 2025 was $6000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $6000.0, changed 0.0% from the prior year.
- Other Non-Current Assets retreated to $6000.0 in Q4 2025 per MENS's latest filing, from $7000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7000.0 in Q2 2025 and bottomed at $6000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Dec 31, 2024 | 6,000.00 |